So should Vaxcyte (NASDAQ:PCVX) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn ...

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other debt free mid ...

In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against other up and coming stocks to buy according to Wall Street Analysts. Tom Lee, Fundstrat managing ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants. Click for PCVX's market opportunity.

In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against Billionaire Stanley Druckenmiller’s other top stock picks with huge upside potential. Wall Street ...

Needham lowered the firm’s price target on Vaxcyte (PCVX) to $90 from $140 and keeps a Buy rating on the shares after the company announced ...

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events.

Vaxcyte (NASDAQ:PCVX – Free Report) had its price target cut by The Goldman Sachs Group from $138.00 to $100.00 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on ...

In its fourth quarter 2024 investor letter, Carillon Eagle Small Cap Growth Fund emphasized stocks such as Vaxcyte, Inc. (NASDAQ:PCVX). Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage ...